Oncotelic Therapeutics, INC S-1 registration statements
Registration statements, filed ahead of a public offering, with the business description and financials a first-time investor sees.
OQB
Oncotelic Therapeutics, a clinical-stage biopharmaceutical company, filed an S-1/A registration statement for the resale of 115.6 million common shares by Mast Hill Fund, LP, while continuing to face substantial doubt about its ability to continue as a going concern.
OQB
Oncotelic Therapeutics files S-1 for resale of 309.7 million shares by Mast Hill Fund, highlighting significant dilution and ongoing financial challenges despite pipeline progress.